Finch Therapeutics Group, Inc., (FNCH) News

Finch Therapeutics Group, Inc., (FNCH): $2.71

-0.17 (-5.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FNCH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter FNCH News Items

FNCH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FNCH News Highlights

  • FNCH's 30 day story count now stands at 2.
  • Over the past 13 days, the trend for FNCH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIOL and MD are the most mentioned tickers in articles about FNCH.

Latest FNCH News From Around the Web

Below are the latest news stories about Finch Therapeutics Group Inc that investors may wish to consider to help them evaluate FNCH as an investment opportunity.

Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit

SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in a panel discussion at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 3:15 pm ET. A

Yahoo | February 23, 2022

Finch Therapeutics Announces Additions to Senior Leadership Team

Bryan Gillis, MBA, appointed Chief Technology OfficerAlka Batycky, PhD, appointed Chief Development OfficerHoward Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biol

Yahoo | February 10, 2022

First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ...

Joliet, IL, based Investment company First Midwest Bank Trust Division (Current Portfolio) buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares Russell Mid-Cap ETF, ISHARES TRUST, Aurinia Pharmaceuticals Inc, sells Iovance Biotherapeutics Inc, Consumer Discretionary Select Sector SPDR, AT&T Inc, Avis Budget Group Inc, Cerus Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Midwest Bank Trust Division.

Yahoo | January 18, 2022

Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ: FNCH ), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Patent and Trademark Office has issued two new patents covering the company''s FIN-211 enriched consortia microbiome product candidate in development for children with autism spectrum disorder (ASD) and significant gastrointestinal (GI) symptoms. The company''s intellectual property portfolio now includes 59 issued U.S. and foreign patents with more than 130 patent applications pending. The first patent (U.S. Patent No. 11,202,808) covers key technologies involved ...

Benzinga | January 6, 2022

Finch Therapeutics gets 2 US patents for FIN-211 to treat autism spectrum disorder

No summary available.

Seeking Alpha | January 6, 2022

Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

SOMERVILLE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a corporate overview at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. I

Yahoo | January 4, 2022

Finch Therapeutics up 10% following large insider buy

No summary available.

Seeking Alpha | December 23, 2021

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Nicholas Haft Acquires 63,850 Shares

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Nicholas Haft purchased 63,850 shares of the business’s stock in a transaction on Monday, December 20th. The shares were acquired at an average price of $10.18 per share, for a total transaction of $649,993.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […]

Dakota Financial News | December 23, 2021

Trade Alert: The Independent Director Of Finch Therapeutics Group, Inc. (NASDAQ:FNCH), Nicholas Haft, Has Just Spent US$650k Buying 1.6% More Shares

Finch Therapeutics Group, Inc. ( NASDAQ:FNCH ) shareholders (or potential shareholders) will be happy to see that the...

Yahoo | December 23, 2021

Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer. Mr. Vittiglio has more than 25 years of experience leading strategic transactions within the life sciences indus

Yahoo | December 20, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5491 seconds.